JP2008540363A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008540363A5 JP2008540363A5 JP2008509380A JP2008509380A JP2008540363A5 JP 2008540363 A5 JP2008540363 A5 JP 2008540363A5 JP 2008509380 A JP2008509380 A JP 2008509380A JP 2008509380 A JP2008509380 A JP 2008509380A JP 2008540363 A5 JP2008540363 A5 JP 2008540363A5
- Authority
- JP
- Japan
- Prior art keywords
- helix
- nucleic acid
- nucleotides
- segmental
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002773 nucleotide Substances 0.000 claims 36
- 125000003729 nucleotide group Chemical group 0.000 claims 36
- 239000000203 mixture Substances 0.000 claims 22
- 108020004707 nucleic acids Proteins 0.000 claims 16
- 102000039446 nucleic acids Human genes 0.000 claims 16
- 150000007523 nucleic acids Chemical class 0.000 claims 16
- NPOAOTPXWNWTSH-UHFFFAOYSA-N 3-hydroxy-3-methylglutaric acid Chemical group OC(=O)CC(O)(C)CC(O)=O NPOAOTPXWNWTSH-UHFFFAOYSA-N 0.000 claims 13
- 102000009012 HMGA Proteins Human genes 0.000 claims 13
- 108010049069 HMGA Proteins Proteins 0.000 claims 13
- 230000027455 binding Effects 0.000 claims 12
- 239000003981 vehicle Substances 0.000 claims 12
- 238000005192 partition Methods 0.000 claims 9
- 102000027411 intracellular receptors Human genes 0.000 claims 8
- 108091008582 intracellular receptors Proteins 0.000 claims 8
- 206010028980 Neoplasm Diseases 0.000 claims 7
- 108091027076 Spiegelmer Proteins 0.000 claims 7
- 210000004027 cell Anatomy 0.000 claims 7
- 229920002873 Polyethylenimine Polymers 0.000 claims 6
- 230000003834 intracellular effect Effects 0.000 claims 6
- 108700039142 HMGA1a Proteins 0.000 claims 5
- 102000049983 HMGA1a Human genes 0.000 claims 5
- 108700039144 HMGA1b Proteins 0.000 claims 5
- 108700039143 HMGA2 Proteins 0.000 claims 5
- 102100029009 High mobility group protein HMG-I/HMG-Y Human genes 0.000 claims 5
- 102100028999 High mobility group protein HMGI-C Human genes 0.000 claims 5
- 101150073387 Hmga2 gene Proteins 0.000 claims 5
- 101000986380 Homo sapiens High mobility group protein HMG-I/HMG-Y Proteins 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 238000009396 hybridization Methods 0.000 claims 5
- 238000000034 method Methods 0.000 claims 5
- 102000052510 DNA-Binding Proteins Human genes 0.000 claims 4
- 108700020911 DNA-Binding Proteins Proteins 0.000 claims 4
- 108091023040 Transcription factor Proteins 0.000 claims 4
- 102000040945 Transcription factor Human genes 0.000 claims 4
- 206010061289 metastatic neoplasm Diseases 0.000 claims 3
- 238000012986 modification Methods 0.000 claims 3
- 230000004048 modification Effects 0.000 claims 3
- 206010003210 Arteriosclerosis Diseases 0.000 claims 2
- 206010005969 Bone giant cell tumour Diseases 0.000 claims 2
- 208000011691 Burkitt lymphomas Diseases 0.000 claims 2
- 208000021994 Diffuse astrocytoma Diseases 0.000 claims 2
- 206010024612 Lipoma Diseases 0.000 claims 2
- 206010025323 Lymphomas Diseases 0.000 claims 2
- 206010027476 Metastases Diseases 0.000 claims 2
- 206010029260 Neuroblastoma Diseases 0.000 claims 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims 2
- 206010046798 Uterine leiomyoma Diseases 0.000 claims 2
- 208000036142 Viral infection Diseases 0.000 claims 2
- 208000028435 angiomyxoma Diseases 0.000 claims 2
- 208000011775 arteriosclerosis disease Diseases 0.000 claims 2
- 201000011143 bone giant cell tumor Diseases 0.000 claims 2
- 210000000481 breast Anatomy 0.000 claims 2
- 210000001072 colon Anatomy 0.000 claims 2
- 208000016018 endometrial polyp Diseases 0.000 claims 2
- 201000001169 fibrillary astrocytoma Diseases 0.000 claims 2
- 201000010260 leiomyoma Diseases 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 230000009401 metastasis Effects 0.000 claims 2
- 230000001394 metastastic effect Effects 0.000 claims 2
- 208000009091 myxoma Diseases 0.000 claims 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 2
- 210000000496 pancreas Anatomy 0.000 claims 2
- 210000004786 perivascular cell Anatomy 0.000 claims 2
- 208000004333 pleomorphic adenoma Diseases 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 210000002307 prostate Anatomy 0.000 claims 2
- 210000003079 salivary gland Anatomy 0.000 claims 2
- 230000011218 segmentation Effects 0.000 claims 2
- 201000000849 skin cancer Diseases 0.000 claims 2
- 210000002784 stomach Anatomy 0.000 claims 2
- 210000001685 thyroid gland Anatomy 0.000 claims 2
- 201000007954 uterine fibroid Diseases 0.000 claims 2
- 206010046811 uterine polyp Diseases 0.000 claims 2
- 230000009385 viral infection Effects 0.000 claims 2
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 claims 1
- 201000005262 Chondroma Diseases 0.000 claims 1
- 229920000858 Cyclodextrin Polymers 0.000 claims 1
- 208000002927 Hamartoma Diseases 0.000 claims 1
- 108010076504 Protein Sorting Signals Proteins 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 208000016160 chondroid hamartoma Diseases 0.000 claims 1
- 229940097362 cyclodextrins Drugs 0.000 claims 1
- 239000000412 dendrimer Substances 0.000 claims 1
- 229920000736 dendritic polymer Polymers 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000003596 drug target Substances 0.000 claims 1
- 238000004520 electroporation Methods 0.000 claims 1
- 230000001159 endocytotic effect Effects 0.000 claims 1
- 230000000799 fusogenic effect Effects 0.000 claims 1
- 238000011534 incubation Methods 0.000 claims 1
- 239000002502 liposome Substances 0.000 claims 1
- 230000003211 malignant effect Effects 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 239000000693 micelle Substances 0.000 claims 1
- 239000011859 microparticle Substances 0.000 claims 1
- 239000002105 nanoparticle Substances 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 230000035939 shock Effects 0.000 claims 1
- 150000003384 small molecules Chemical class 0.000 claims 1
- 238000002604 ultrasonography Methods 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102005020874 | 2005-05-04 | ||
| PCT/EP2006/004180 WO2006117217A2 (de) | 2005-05-04 | 2006-05-04 | Neue verwendung von spiegelmeren |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013129800A Division JP5766750B2 (ja) | 2005-05-04 | 2013-06-20 | シュピーゲルマーの新規な使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008540363A JP2008540363A (ja) | 2008-11-20 |
| JP2008540363A5 true JP2008540363A5 (enExample) | 2009-06-25 |
Family
ID=36928624
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008509380A Pending JP2008540363A (ja) | 2005-05-04 | 2006-05-04 | シュピーゲルマーの新規な使用 |
| JP2013129800A Expired - Fee Related JP5766750B2 (ja) | 2005-05-04 | 2013-06-20 | シュピーゲルマーの新規な使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013129800A Expired - Fee Related JP5766750B2 (ja) | 2005-05-04 | 2013-06-20 | シュピーゲルマーの新規な使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US8497250B2 (enExample) |
| EP (2) | EP1877069A2 (enExample) |
| JP (2) | JP2008540363A (enExample) |
| KR (2) | KR101418367B1 (enExample) |
| CN (2) | CN101217967B (enExample) |
| AU (1) | AU2006243334A1 (enExample) |
| BR (1) | BRPI0610367A2 (enExample) |
| CA (1) | CA2607185A1 (enExample) |
| MX (1) | MX2007013760A (enExample) |
| SG (1) | SG161311A1 (enExample) |
| WO (1) | WO2006117217A2 (enExample) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007001448A2 (en) | 2004-11-04 | 2007-01-04 | Massachusetts Institute Of Technology | Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals |
| US9267937B2 (en) | 2005-12-15 | 2016-02-23 | Massachusetts Institute Of Technology | System for screening particles |
| WO2008105773A2 (en) | 2006-03-31 | 2008-09-04 | Massachusetts Institute Of Technology | System for targeted delivery of therapeutic agents |
| US8367113B2 (en) | 2006-05-15 | 2013-02-05 | Massachusetts Institute Of Technology | Polymers for functional particles |
| WO2007150030A2 (en) | 2006-06-23 | 2007-12-27 | Massachusetts Institute Of Technology | Microfluidic synthesis of organic nanoparticles |
| US9217129B2 (en) | 2007-02-09 | 2015-12-22 | Massachusetts Institute Of Technology | Oscillating cell culture bioreactor |
| US20090074828A1 (en) | 2007-04-04 | 2009-03-19 | Massachusetts Institute Of Technology | Poly(amino acid) targeting moieties |
| MX2010003642A (es) | 2007-10-12 | 2010-08-09 | Massachusetts Inst Technology | Nanotecnologia de vacuna. |
| US8343498B2 (en) | 2008-10-12 | 2013-01-01 | Massachusetts Institute Of Technology | Adjuvant incorporation in immunonanotherapeutics |
| US8343497B2 (en) | 2008-10-12 | 2013-01-01 | The Brigham And Women's Hospital, Inc. | Targeting of antigen presenting cells with immunonanotherapeutics |
| US8277812B2 (en) | 2008-10-12 | 2012-10-02 | Massachusetts Institute Of Technology | Immunonanotherapeutics that provide IgG humoral response without T-cell antigen |
| US8591905B2 (en) | 2008-10-12 | 2013-11-26 | The Brigham And Women's Hospital, Inc. | Nicotine immunonanotherapeutics |
| WO2010138193A2 (en) | 2009-05-27 | 2010-12-02 | Selecta Biosciences, Inc. | Targeted synthetic nanocarriers with ph sensitive release of immunomodulatory agents |
| US20130149314A1 (en) * | 2010-02-09 | 2013-06-13 | Jörn Bullerdiek | p19Arf, HMGA2 and MDM2 For Use in the Diagnosis and Treatment of Aberrant Cell Growth |
| US8871920B2 (en) | 2010-04-21 | 2014-10-28 | Noxxon Pharma Ag | Lipid binding nucleic acids |
| CN107029223A (zh) | 2010-05-26 | 2017-08-11 | 西莱克塔生物科技公司 | 合成纳米载体联合疫苗 |
| CN102375064A (zh) * | 2010-08-26 | 2012-03-14 | 杭州华得森生物技术有限公司 | 用酶联免疫法检测人体中hmga2含量的体外诊断试剂盒 |
| DE102010056610A1 (de) * | 2010-12-31 | 2012-07-05 | Volker A. Erdmann | Pharmazeutische Zusammensetzung enthaltend L-DNA |
| JP2014521687A (ja) | 2011-07-29 | 2014-08-28 | セレクタ バイオサイエンシーズ インコーポレーテッド | 体液性および細胞傷害性ｔリンパ球（ｃｔｌ）免疫応答を生成する合成ナノキャリア |
| SG11201401362TA (en) * | 2011-10-21 | 2014-05-29 | Noxxon Pharma Ag | Glucagon binding nucleic acids |
| EP2802659A1 (en) * | 2012-01-10 | 2014-11-19 | Noxxon Pharma AG | Nucleic acids specifically binding cgrp |
| CN112587671A (zh) | 2012-07-18 | 2021-04-02 | 博笛生物科技有限公司 | 癌症的靶向免疫治疗 |
| US9233119B2 (en) * | 2012-09-27 | 2016-01-12 | Miami University | Use of HGMA-targeted phosphorothioate DNA aptamers to suppress carcinogenic activity and increase sensitivity to chemotherapy agents in human cancer cells |
| WO2014193964A2 (en) * | 2013-05-28 | 2014-12-04 | Marsha Rosner | Prognostic and predictive breast cancer signature |
| US10679730B2 (en) | 2013-05-28 | 2020-06-09 | The University Of Chicago | Prognostic and predictive breast cancer signature |
| EP3092256B1 (en) | 2014-01-10 | 2022-05-18 | Birdie Biopharmaceuticals Inc. | Compounds and compositions for immunotherapy |
| CN112546230A (zh) | 2014-07-09 | 2021-03-26 | 博笛生物科技有限公司 | 用于治疗癌症的联合治疗组合物和联合治疗方法 |
| DK4001311T3 (da) | 2014-07-09 | 2026-02-02 | Birdie Biopharmaceuticals Inc | Anti-pd-l1/pd-1-kombinationer til behandling af tumorer |
| KR101755617B1 (ko) | 2014-07-23 | 2017-07-10 | 한국과학기술연구원 | 삼차원 자기조립 핵산 나노입자 구조를 갖는 약물전달체 |
| CN112546238A (zh) | 2014-09-01 | 2021-03-26 | 博笛生物科技有限公司 | 用于治疗肿瘤的抗-pd-l1结合物 |
| US10327946B2 (en) * | 2014-12-19 | 2019-06-25 | Kemin Industries, Inc. | Intraocular delivery of bioactive molecules using iontophoresis |
| US20180153884A1 (en) | 2015-05-31 | 2018-06-07 | Curegenix Corporation | Combination compositions for immunotherapy |
| AU2016319126A1 (en) | 2015-09-10 | 2018-04-19 | Affigen, Inc. | Sequencing-directed selection of tumor theranostics |
| BR112019009373A8 (pt) * | 2016-11-30 | 2023-04-11 | Noxxon Pharma Ag | Método para polialcoxilação de ácidos nucleicos que permite recuperação e reutilização do excesso de reagente de polialcoxilação |
| WO2020055663A1 (en) * | 2018-09-11 | 2020-03-19 | The Texas A&M University System | L-oligonucleotide inhibitors of polycomb repressive complex 2 (prc2) |
| US11674957B2 (en) * | 2020-04-30 | 2023-06-13 | Velanidi Technologies LLC | Molecular wires for detecting a biological or chemical entity or event |
| CN112725438B (zh) * | 2021-02-05 | 2023-08-22 | 深圳市宝安区妇幼保健院 | 子宫内膜息肉甲基化标志物组合、检测试剂盒及应用 |
| CN114807183B (zh) * | 2021-12-06 | 2023-06-02 | 西藏自治区农牧科学院农业研究所 | 一种青稞矢车菊素氧甲基转移酶基因的新用途 |
| CN118311277B (zh) * | 2024-06-11 | 2024-12-31 | 北京卫未科学技术有限公司 | 一种用于癌症早筛和辅助诊断的试剂盒及其应用 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5622828A (en) * | 1990-06-11 | 1997-04-22 | Nexstar Pharmaceuticals, Inc. | High-affinity oligonucleotide ligands to secretory phospholipase A2 (sPLA2) |
| EP0724647A4 (en) * | 1993-09-08 | 2003-09-17 | Gilead Sciences Inc | NUCLEIC ACIDS AS LIGANDS AND IMPROVED PRODUCTION METHODS |
| ES2336857T3 (es) * | 1995-05-04 | 2010-04-16 | Gilead Sciences, Inc. | Complejos de ligandos de acido nucleico. |
| US5780611A (en) * | 1995-09-15 | 1998-07-14 | Ramareddy Venkata Guntaka | Oligomers which inhibit expression of collagen genes |
| US6171779B1 (en) | 1996-07-12 | 2001-01-09 | University Of Medicine & Dentistry Of New Jersey | HMGI proteins in cancer |
| ES2188985T3 (es) * | 1996-08-30 | 2003-07-01 | Jens Peter Furste | Seleccion enantiomerica y evolucion enantiomerica de acidos nucleicos. |
| DE19726186A1 (de) * | 1997-06-20 | 1998-12-24 | Boehringer Ingelheim Int | Komplexe für den Transport von Nukleinsäure in höhere eukaryotische Zellen |
| AU2001289943A1 (en) * | 2000-10-09 | 2002-04-22 | Bayer Aktiengesellschaft | Complexes for transferring nucleic acids into cells |
| DE10118452A1 (de) * | 2001-04-12 | 2002-10-31 | Joern Bullerdiek | Nukleinsäuresequenzen von Hyperplasien und Tumoren der Schilddrüse |
| EP1438321B1 (de) * | 2001-10-26 | 2010-05-26 | Noxxon Pharma AG | Modifizierte l-nukleinsäure |
| ATE395602T1 (de) * | 2001-12-19 | 2008-05-15 | Alcedo Biotech Gmbh | Verwendung von hmgb-proteinen und dafür codierenden nukleinsäuren |
| DE10211558A1 (de) | 2002-03-15 | 2003-10-09 | Noxxon Pharma Ag | Neue Formen RNAi |
| WO2003094973A1 (de) | 2002-05-08 | 2003-11-20 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Mittel und verfahren zum transport von biologisch aktiven molekülen in zellen |
| US7250496B2 (en) * | 2002-11-14 | 2007-07-31 | Rosetta Genomics Ltd. | Bioinformatically detectable group of novel regulatory genes and uses thereof |
| EP1579221A2 (de) * | 2003-01-03 | 2005-09-28 | Alcedo Biotech GmbH | Verwendungen von hmgb, hmgn, hmga proteinen |
| AU2004230927B9 (en) * | 2003-04-13 | 2011-12-01 | Enzon Pharmaceuticals, Inc. | Polymeric oligonucleotide prodrugs |
| WO2004100928A1 (de) * | 2003-05-09 | 2004-11-25 | Novosom Ag | Injizierbare liposomale depots zum wirkstoffdelivery |
| CA2526853A1 (en) | 2003-05-23 | 2005-03-03 | Board Of Regents - The University Of Texas System | Structure based and combinatorially selected oligonucleoside phosphorothioate and phosphorodithioate aptamer targeting ap-1 transcription factors |
| US7727969B2 (en) * | 2003-06-06 | 2010-06-01 | Massachusetts Institute Of Technology | Controlled release nanoparticle having bound oligonucleotide for targeted delivery |
| WO2005072703A2 (en) * | 2004-01-26 | 2005-08-11 | Control Delivery Systems, Inc. | Controlled and sustained delivery of nucleic acid-based therapeutic agents |
| BRPI0519468A2 (pt) * | 2004-12-27 | 2009-01-27 | Silence Therapeutics Ag | complexos de lipÍdeos revestido e seu uso |
-
2006
- 2006-05-04 MX MX2007013760A patent/MX2007013760A/es unknown
- 2006-05-04 EP EP06742799A patent/EP1877069A2/de not_active Ceased
- 2006-05-04 CA CA002607185A patent/CA2607185A1/en not_active Abandoned
- 2006-05-04 CN CN200680024585.4A patent/CN101217967B/zh not_active Expired - Fee Related
- 2006-05-04 WO PCT/EP2006/004180 patent/WO2006117217A2/de not_active Ceased
- 2006-05-04 EP EP09016125A patent/EP2206501A3/de not_active Withdrawn
- 2006-05-04 KR KR1020147008135A patent/KR101418367B1/ko not_active Expired - Fee Related
- 2006-05-04 JP JP2008509380A patent/JP2008540363A/ja active Pending
- 2006-05-04 AU AU2006243334A patent/AU2006243334A1/en not_active Abandoned
- 2006-05-04 KR KR1020077025457A patent/KR101418369B1/ko not_active Expired - Fee Related
- 2006-05-04 BR BRPI0610367-7A patent/BRPI0610367A2/pt not_active IP Right Cessation
- 2006-05-04 CN CN201410395203.5A patent/CN104293780A/zh active Pending
- 2006-05-04 SG SG201002837-1A patent/SG161311A1/en unknown
- 2006-05-04 US US11/913,526 patent/US8497250B2/en not_active Expired - Fee Related
-
2013
- 2013-06-20 JP JP2013129800A patent/JP5766750B2/ja not_active Expired - Fee Related
- 2013-07-30 US US13/953,797 patent/US9074214B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102262260B1 (ko) | 엔도좀 탈출능을 갖는 펩티드 핵산 복합체 및 이의 용도 | |
| KR101963885B1 (ko) | 세포투과성이 향상된 펩티드 핵산 복합체 및 이를 포함하는 약학적 조성물 | |
| JP6060178B2 (ja) | 高効率のナノ粒子型二本鎖オリゴｒｎａ構造体およびその製造方法 | |
| KR101867414B1 (ko) | 호흡기 질환 연관 유전자 특이적 siRNA, 그러한 siRNA를 포함하는 이중나선 올리고 RNA 구조체 및 이를 포함하는 호흡기 질환 예방 또는 치료용 조성물 | |
| US9289505B2 (en) | Compositions and methods for delivering nucleic acid molecules and treating cancer | |
| CN105705638B (zh) | 改善的具有高效能的纳米颗粒型寡核苷酸结构及其制备方法 | |
| JP5906327B2 (ja) | 磁性ナノ粒子−ＳＡＭｉＲＮＡ複合体およびその製造方法 | |
| US20110123988A1 (en) | Antisense compounds and methods for diagnostic imaging | |
| EP2190482A2 (en) | Targeted block copolymer micelles | |
| Golan et al. | Conjugates of HA2 with octaarginine-grafted HPMA copolymer offer effective siRNA delivery and gene silencing in cancer cells | |
| US10155946B2 (en) | Particle-nucleic acid conjugates and therapeutic uses related thereto | |
| CA3089396A1 (en) | Nanoparticle-hydrogel composite for nucleic acid molecule delivery | |
| US11008575B2 (en) | DNA aptamers against cancer and uses thereof in delivery of therapy and diagnosis of cancer | |
| CN114364404A (zh) | 寡核苷酸-聚合物多手臂偶联物以及使用方法 | |
| KR101715228B1 (ko) | 뎅기 바이러스 특이적 siRNA, 그러한 siRNA 를 포함하는 이중나선 올리고 RNA 구조체 및 이를 포함하는 뎅기 바이러스 증식 억제용 조성물 | |
| JP5510808B2 (ja) | 有機ナノチューブからなる核酸導入剤 | |
| JP2013504337A (ja) | 標的特異的ｓｉＲＮＡ−層状無機水酸化物ナノハイブリッド、その製造方法、及びナノハイブリッドを含有する腫瘍治療用の医薬組成物 | |
| Mohammed-Saeid et al. | Design and evaluation of gemini surfactant-based lipoplexes modified with cell-binding peptide for targeted gene therapy in melanoma model | |
| JP2003526692A (ja) | ポリヌクレオチド組成物 | |
| WO2016109522A1 (en) | Particle-nucleic acid conjugates and therapeutic uses related thereto | |
| WO2026061476A1 (zh) | 一种多簇连接子、其制备方法及应用 | |
| KR101722948B1 (ko) | 리간드가 결합된 이중나선 올리고 ｒｎａ 구조체 및 그 제조방법 | |
| Mohammed-Saeid et al. | Design and Evaluation of Gemini Surfactant-Based Lipoplexes Modified with Cell-Binding Peptide for Targeted Gene Therapy | |
| Chen | Macrophage targeting using nanotechnology for HIV therapy | |
| HK40002750B (en) | Peptide nucleic acid complex having improved cell permeability and pharmaceutical composition comprising same |